Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MTTP | P55157 | 6/20 | 0.47 |
| ▸ | APOB | P04114 | 3/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794188 | 0.94 | ALDH1A1 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4TRPV1 | |
| SCHEMBL6799294 | 0.90 | KMT2A (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4TRPV1 | |
| SCHEMBL6793203 | 0.88 | TRPV1 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4TRPV1 | |
| SCHEMBL6795714 | 0.86 | TRPV1 (0.53) | TRPV1SMOKDRMTTPAPOB | |
| SCHEMBL6792600 | 0.85 | KDR (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4TRPV1 | |
| SCHEMBL6793985 | 0.85 | SMO (0.60) | TRPV1SMOKDRMTTPAPOB | |
| SCHEMBL6799166 | 0.85 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4TRPV1 | |
| SCHEMBL6801569 | 0.85 | TRPV1 (0.68) | CHRNB2CHRNB4CHRNA3CHRNA4TRPV1 | |
| SCHEMBL6793626 | 0.85 | NAMPT (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4TRPV1 | |
| SCHEMBL6793585 | 0.84 | SMO (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | CHRNB2 1763/4885CHRNB4 2366/4885CHRNA3 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.